PMID- 15982353
OWN - NLM
STAT- MEDLINE
DCOM- 20050930
LR  - 20161124
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 130
IP  - 1
DP  - 2005 Jul
TI  - Impaired bradykinin response to ischaemia and exercise in patients with mild 
      congestive heart failure during angiotensin-converting enzyme treatment. 
      Relationships with endothelial function, coagulation and inflammation.
PG  - 113-20
AB  - Inflammation and endothelial dysfunction play important roles in the 
      pathophysiology of congestive heart failure (CHF), and the peptide bradykinin, 
      generated during inflammation, may act as a defence mechanism by inducing 
      vasodilation. Plasma bradykinin levels are increased in experimental heart 
      failure but low in patients with advanced chronic CHF despite treatment with 
      angiotensin-converting enzyme (ACE) inhibitors. It is not currently known how 
      bradykinin behaves in less severe phases of CHF controlled by long-term ACE 
      inhibitor treatment. We studied 10 male patients with clinically stable chronic 
      CHF [New York Heart Association (NYHA) class II] on long-term ACE inhibitor 
      treatment and 10 normal sex- and age-matched control subjects. High performance 
      liquid chromatography/radioimmunoassay methods were used to evaluate plasma 
      levels of bradykinin in relation to an array of parameters of endothelial 
      function, coagulation and inflammation before and after stimuli of forearm 
      arterial occlusion and physical exercise. CHF patients had higher levels of 
      bradykinin (P = 0.008), activated factor XII (P = 0.049), interleukin-6 (P = 
      0.050) and tumour necrosis factor receptor II (sTNFRII) (P = 0.026) than 
      controls. Arterial occlusion and exercise significantly increased bradykinin and 
      von Willebrand factor levels in controls but not in CHF patients. The increase in 
      brachial artery diameter after arterial occlusion was less in CHF patients (P = 
      0.036) and inversely related to baseline plasma levels of bradykinin (r = -0.855, 
      P = 0.002) and sTNFRII (r = -0.780, P = 0.008). NYHA class II CHF patients during 
      long-term treatment with ACE inhibitors have increased bradykinin levels and 
      signs of inflammation. They are unable to respond adequately to stimuli of 
      ischaemia and physical exercise which both require vasodilation.
FAU - Cugno, Massimo
AU  - Cugno M
AD  - Department of Internal Medicine, University of Milan, Milan, Italy. 
      massimo.cugno@unimi.it
FAU - Agostoni, Piergiuseppe
AU  - Agostoni P
FAU - Mari, Daniela
AU  - Mari D
FAU - Meroni, Pier Luigi
AU  - Meroni PL
FAU - Gregorini, Luisa
AU  - Gregorini L
FAU - Bussotti, Maurizio
AU  - Bussotti M
FAU - Anguissola, Gian Battista
AU  - Anguissola GB
FAU - Donatelli, Francesco
AU  - Donatelli F
FAU - Nussberger, Jurg
AU  - Nussberger J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 0 (von Willebrand Factor)
RN  - E7199S1YWR (Lisinopril)
RN  - EC 3.4.21.38 (Factor XIIa)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Adult
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Coagulation Factors/analysis
MH  - Brachial Artery/diagnostic imaging
MH  - Bradykinin/*blood
MH  - Case-Control Studies
MH  - Endothelium, Vascular/physiopathology
MH  - *Exercise
MH  - Factor XIIa/analysis
MH  - Heart Failure/*blood/*drug therapy/physiopathology
MH  - Humans
MH  - Interleukin-6/blood
MH  - Ischemia/physiopathology
MH  - Lisinopril/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor, Type II/blood
MH  - Tissue Plasminogen Activator/analysis
MH  - Ultrasonography
MH  - Vasodilation
MH  - von Willebrand Factor/analysis
EDAT- 2005/06/29 09:00
MHDA- 2005/10/01 09:00
CRDT- 2005/06/29 09:00
PHST- 2005/06/29 09:00 [pubmed]
PHST- 2005/10/01 09:00 [medline]
PHST- 2005/06/29 09:00 [entrez]
AID - BJH5569 [pii]
AID - 10.1111/j.1365-2141.2005.05569.x [doi]
PST - ppublish
SO  - Br J Haematol. 2005 Jul;130(1):113-20. doi: 10.1111/j.1365-2141.2005.05569.x.